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Abstract
Background: Evidence that chemotherapy improves survival and quality of life in patients with
stage IIIB & IV non small cell lung cancer (NSCLC) is based on large randomized controlled trials.
The purpose of this study was to determine eligibility of patients with advanced NSCLC for major
chemotherapy trials.
Methods: Physicians treating stage IIIB/IV NSCLC at Sydney Cancer Centre assessed patient
eligibility for the E1594, SWOG9509 and TAX326 trials for patients presenting from October 2001
to December 2002. A review of the centre's registry was used to obtain missing data.
Results:  199 patients with advanced NSCLC were registered during the 14-month period.
Characteristics of 100 patients were defined prospectively, 85 retrospectively: 77% males, median
age 68 (range 32–88), 64% stage IV disease. Only 35% met trial eligibility for E1594 and 28% for
SWOG9509 and TAX326. Common reasons for ineligibility were: co-morbidities 75(40%); ECOG
Performance Status ≥2 72(39%); symptomatic brain metastasis 15(8%); and previous cancers
21(11%). Many patients were ineligible by more than one criterion.
Conclusion:  The majority of patients with advanced NSCLC were ineligible for the large
chemotherapy trials. The applicability of trial results to advanced lung cancer populations may be
limited. Future trials should be conducted in a more representative population.
Background
There is level one evidence that patients with stage IIIB
and IV non-small cell lung cancer (NSCLC) and good per-
formance status benefit from chemotherapy, both in
terms of survival and improved quality of life. A meta-
analysis by the Non-Small Cell Lung Cancer Collaborative
Group, comparing best supportive care (BSC) with BSC
and chemotherapy reported a 27% reduction in the risk of
death (p < 0.0001), with an increase in median survival of
1.5 months, in patients receiving cisplatin-based chemo-
therapy[1]. A phase III study randomising patients with
stage IIIB (pleural effusion) or IV NSCLC to BSC or BSC
and chemotherapy with mitomycin C, ifosfamide and cis-
platin (MIC2), found a median survival of 6.7 months in
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the chemotherapy arm compared with 4.8 months in the
BSC arm (p = 0.03)[2]. Quality of life improved from
baseline to six weeks in the chemotherapy arm and dete-
riorated in the BSC arm (p = 0.007)[2]. A systematic
review by Clegg found that the chemotherapeutic agents
paclitaxel, docetaxel, gemicitabine and virorelbine
improved survival in advanced NSCLC by 2–4 months
compared to BSC, without compromising quality of life
and that it was cost effective. [3]
Although the large chemotherapy versus BSC trials, and
the more recent combination chemotherapy trials,
reported a significant benefit from chemotherapy in both
survival and quality of life in advanced NSCLC, all were
performed in relatively young, highly selected groups of
patients.
Some of the more influential recent studies performed for
patients with NSCLC have included (i) European Co-
operative Oncology Group (ECOG) E1594[4], (ii) South
Western Oncology Group SWOG 9509[5] and (iii) TAX
326[6]. The ECOG 1594 trial compared paclitaxel and cis-
platin with the following regimens: gemcitabine and cis-
platin; docetaxel and cisplatin; or paclitaxel and
carboplatin in 1155 patients. There was no difference in
response rate (19%), median survival (7.9 months) or 1-
year survival (33%) between the four arms. Time to pro-
gression was significantly better in the gemcitabine/cispl-
atin arm but there was greater renal toxicity. Initially
patients with ECOG PS 2 were eligible, but the criteria
were changed to exclude them after it became evident that
patients with PS 2 had a significantly higher rate of
adverse events than PS 0–1. Median survival in patients
with PS 0 was 10.8 months, PS 1 7.1 months and in PS 2
3.9 months (p < 0.001)[4].
SWOG 9509 enrolled 406 patients with advanced NSCLC,
all with ECOG performance status 0–1. Patients were ran-
domised to receive either vinorelbine and cisplatin, or
paclitaxel and carboplatin. There was no difference in
median survival, 1 or 2 year survival or quality of life[5].
TAX326 randomised 1218 patients to receive either
docetaxel and cisplatin, docetaxel and carboplatin or
vinorelbine and cisplatin. Patients receiving docetaxel and
cisplatin had a median survival of 11.3 months compared
to 10.1 months for vinorelbine/cisplatin (p = 0.044), with
no significant difference in median survival between
vinorelbine/cisplatin and docetaxel/carboplatin, but
poorer quality of life in the vinorelbine arm [6].
The highly selected patients treated in these clinical trials
raises doubts about the applicability of their results to
other patients with lung cancer. We therefore designed a
questionnaire to determine how many of the total pool of
patients with advanced NSCLC presenting to the Sydney
Cancer Centre (excluding the Palliative Care department)
would have been eligible for these recent randomised tri-
als of chemotherapy and to document the reasons for
ineligibility.
Methods
Patients were recruited from the Royal Prince Alfred Hos-
pital and Concord Repatriation General Hospital, Sydney,
Australia from October 2001 until December 2002. Ethics
committee approval was obtained from both participat-
ing hospitals. All physicians from Medical Oncology,
Radiation Oncology, Respiratory Medicine and Thoracic
Surgery were requested to complete a questionnaire at the
time of the initial consultation for each new patient with
Stage IIIB (pleural effusion) and Stage IV NSCLC present-
ing to their service. Basic demographic information was
collected and histological subtype and staging was
recorded as well as the presence (or not) of measurable or
evaluable disease. Information on co-morbidities, prior
history of malignancy and laboratory tests, including full
blood count, liver function tests and creatinine, were
recorded. Any previous treatment for lung cancer was doc-
umented and Eastern Co-operative Oncology Group
(ECOG) performance status (PS) was evaluated. Physi-
cians were asked to estimate patient's life expectancy as
less than or greater than 12 weeks, to document weight
loss of greater than 10% in the past 6 weeks, and to assess
whether the patient was capable of giving informed con-
sent. Patients seen by more than one service were only
counted once.
All patients referred to the Sydney Cancer Centre are reg-
istered in a data base. This cancer registry was reviewed to
determine how many patients with advanced NSCLC had
been referred to the service during this period. A retrospec-
tive review of the medical records of patients not evalu-
ated prospectively was undertaken to obtain as much
information as possible: the hospital and oncology medi-
cal records were reviewed, the individual specialist was
contacted and the hospital electronic pathology, labora-
tory and imaging results were examined.
Each patient's data were then reviewed to determine
whether or not they met the eligibility criteria for each of
the following trials: (i) ECOG E1594, (ii) SWOG 9509
and (iii) TAX 326.
Statistical methods
Descriptive methods were used to summarise demo-
graphic characteristics. Analysis involved simple summary
statistics, performed on Excel. Analysis of the prospective
and retrospective data are presented separately as well as
combined. Where information was unobtainable retro-
spectively (e.g. life expectancy) a conservative estimate
was assumed. Where no evidence could be found that a
patient had attended any appointment or had any investi-BMC Cancer 2009, 9:130 http://www.biomedcentral.com/1471-2407/9/130
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gations, it was assumed that they had been a non-attendee
and they were excluded from the data set.
Results
A total of 199 patients with advanced NSCLC were regis-
tered in the Sydney Cancer Centre data base between Octo-
ber 2001 and December 2002. Prospective questionnaires
were obtained for 100 patients and data from retrospective
chart review for an additional 85 patients. There were a fur-
ther 14 patients who were registered but for whom no evi-
dence could be found of their attending Sydney Cancer
Centre or of having investigations during this period.
Patient characteristics are shown in table 1. The median
age of the entire cohort was 68 years (age range 32–88
years) with 77% males and 23% females. Sixty-six patients
(36%) had Stage IIIB disease, and 119 (64%) had stage IV
disease. The most common histological diagnoses were:
large cell 78 (42%), adenocarcinoma 67 (36%) and squa-
mous cell carcinoma 23 (12%).
Using the combined prospective and retrospective data set
64/185 (34%) patients were eligible for E1594, 53 (28%)
for SWOG 9509 and 52 (28%) for TAX326: this included
3 patients for whom there were inadequate data to deter-
mine eligibility. (Table 2) Many patients were ineligible
on more than one criterion. In the E1594 study 71 (38%)
patients, and in the SWOG 9509 study 75 (40.5%), were
ineligible on at least two criteria. (Table 3).
The major reasons for ineligibility are outlined in Table 4.
Seventy two (39%) were ineligible for all three trials due
to a performance status of 2 or worse. This included 39
patients who were ECOG performance status 2; of whom
only 15/39 (38%) met all other eligibility criteria for
SWOG 9509 or TAX326.
Seventy-five patients (40.5%) would have been excluded
from SWOG 9509 and TAX326 for co-morbidities, most
commonly severe or uncontrolled cardiac or pulmonary
disease. The E1594 study has more liberal inclusion crite-
Table 1: Patient Characteristics
Patient Characteristics Prospective Data
n = 100 (%)
Retrospective Data
n = 85 (%)
Total Cohort
n = 185 (%)
Sex:
Males 75 (75%) 68 (80%) 143 (77%)
Females 25 (25%) 17 (20%) 42 (23%)
Median age (years) 66(32–88) 68 (45–84) 68 (32–88)
Mean age 66 67 67
Staging:
Stage IIIB (effusion) 37 (37%) 29 (34%) 66 (36%)
Stage IV 63 (63%) 56 (66%) 119 (64%)
Histological Subtype:
Large cell carcinoma 50 (50%) 28 (33%) 78 (42%)
Adenocarcinoma 36 (36%) 31 (36%) 67 (36%)
Squamous cell carcinoma 10 (10%) 13 (15%) 23 (12%)
Bronchoalveolar 2 (2%) 4 (5%) 6 (3%)
Undifferentiated carcinoma 2 (2%) 4 (5%) 6 (3%)
Mixed 0 (0%) 2 (2%) 2 (1%)
Not available 0 (0%) 3 (3.5%) 3 (2%)
Measurable disease 88 (88%) 82 (96%) 170 (92%)
Evaluable disease 4 (4%) 2 (2%) 6 (3%)
Non-measurable disease 8 (8%) 1 (1%) 9 (5%)
ECOG Performance Status:
ECOG 0 28 (28%) 17 (20%) 45 (24%)
ECOG 1 35 (35%) 26 (30.5%) 61 (33%)
ECOG 2 23 (23%) 15 (18%) 38 (20.5%)
ECOG 3 & 4 14 (14%) 20 (23%) 34 (19%)
Not available 0 (0%) 7 (8%) 7 (4%)
Estimated life expectancy:
<12 weeks 34 (34%) 20 (23.5%) 54 (29%)
>12 weeks 66 (66%) 58 (68%) 124 (67%)
Not available 0 (0%) 7 (8%) 7 (4%)
Weight loss > 10% in 6 weeks 26 (26%) 26 (30.5%) 52 (28%)
Weight loss Not available 0 (0%) 10 (12%) 10 (5%)
Incapable of giving informed consent 1 (1%) 3 (3.5%) 4 (2%)
* retrospective patients were added to the Medical Oncology department referral base
# Blood abnormalities leading to exclusion from SWOG lung trialBMC Cancer 2009, 9:130 http://www.biomedcentral.com/1471-2407/9/130
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ria and would have excluded 50 (27%) patients based on
their co-morbidities. (Table 4)
Across all studies 21 (11%) patients were excluded due to
second malignancies. Fifteen patients were not eligible
because of unstable brain metastasis. Some of these
patients might have subsequently qualified for inclusion
in E1594 after cerebral radiotherapy.
Eleven patients would have been excluded from SWOG
9509 on the basis of abnormal blood test results: most
commonly elevated creatinine and raised bilirubin. In 16
patients, blood results were not available, as they either
hadn't been performed (generally because patients were
too unwell to consider chemotherapy) or they were done
in private laboratories and not available. For the purposes
of determining eligibility these were regarded as being
normal.
Ten patients were ineligible due to non-measurable dis-
ease and twelve patients because they had received prior
chemotherapy.
Discussion
The last decade has seen a shift from studies comparing
BSC with chemotherapy in patients with advanced NSCLC,
to studies comparing different chemotherapy combina-
tions, administered either alone or in combination with
molecular targeted agents, most commonly targeted
against the epidermal growth factor receptor (EGFR) or vas-
cular endothelial growth factor (VEGF). This has resulted in
increasingly complex and expensive treatment regimens,
and it is important that such therapies be evaluated in the
target population. Consequently, we determined whether
the patients enrolled in large chemotherapy trials were typ-
ical of the lung cancer patients presenting to cancer centres.
Eligibility for the newer molecular targeted therapy trials
were not included as these were not widely available at our
centre at the time of this study; however a second study is
in progress to assess this.
Of the 3 trials whose inclusion/exclusion criteria were evalu-
ated, the ECOG-1594 study had the least restrictive criteria
and would have excluded 121 (65%) of our NSCLC patients,
whilst a further 3 had insufficient data available to determine
their eligibility. Of the 61 (33%) that would have met E1594
eligibility criteria, 7 patients were estimated to have a life
expectancy of less than 12 weeks, 4 had severe concomitant
pulmonary disease and eight had weight loss of greater than
10% in the 6 weeks prior to assessment.
Life expectancy was estimated to be less than 12 weeks in
54 (29%) of patients. This is likely a conservative estimate,
as physicians are known to consistently overestimate life
expectancy in people with advanced cancer[7], and where
life expectancy was not documented we assumed it was
greater than 12 weeks. Physicians estimated a life expect-
ancy of <12 weeks in 6 patients who met all eligibility crite-
ria for E1594, SWOG 9509 and TAX 326.
Weight loss is a poor prognostic factor for patients with
advanced NSCLC[8,9] Fifty two (28%) patients had docu-
Table 2: Eligibility for E1594 and SWOG9509
Prospective Data
N = 100 (%)
Retrospective Data
N = 85 (%)
Entire Cohort
N = 185 (%)
E1594:
Ineligible 61 (61%) 60 (70.5%) 121 (65%)
Eligible 39 (39%) 22 (26%) 61 (33%)
Not assessable 0 (0%) 3 (3.5%) 3 (2%)
SWOG 9509
Ineligible 66 (66%) 66 (78%) 132 (71%)
Eligible 34 (34%) 16 (19%) 50 (27%)
Not assessable 0 (0%) 3 (3.5%) 3 (2%)
Table 3: Number (%) of Criteria Resulting in Ineligibility for Trials
No of Criteria No of Patients E1594 No of Patients SWOG9509
Resulting in Ineligibility Prospective Data
N = 100 (%)
Retrospective Data
N = 85 (%)
Entire Cohort
N = 185(%)
Prospective Data
N = 100 (%)
Retrospective Data
N = 85 (%)
Entire Cohort
N = 185 (%)
1 32 (32%) 38 (45%) 71 (38%) 34 (34%) 41 (48%) 75 (40.5%)
2 22 (22%) 11 (13%) 33 (18%) 23 (23%) 12 (14%) 35 (19%)
3 6 (6%) 9 (11%) 15 (8%) 7 (7%) 11 (13%) 18 (10%)
4 1 (1%) 2 (2%) 3 (2%) 2 (2%) 2 (2%) 4 (2%)
* Eligibility for TAX326 is almost identical to SWOG9509 and so is not listed separatelyBMC Cancer 2009, 9:130 http://www.biomedcentral.com/1471-2407/9/130
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mented weight loss of greater than 10% within the preced-
ing six weeks: of these patients 12 (6%) were eligible for
the E1594 trial and 13 (7%) met eligibility criteria for
both the SWOG 9509 and TAX 326 trials.
Excluding patients with ECOG PS of 2–4 immediately
excluded 72 (39%) of our patients with advanced NSCLC.
Of those with a performance status of 2, only 15/39
(38%) would have met all the other eligibility criteria for
SWOG 9509 or TAX326.
Co-morbidities were a major cause of trial ineligibility:
40.5% in SWOG 9509 and 27% in E1594. With approxi-
mately 86% of lung cancers in men and 49% in women
being current smokers, or having a significant past history
of smoking[10], it is not surprising that there is a high rate
of co-morbidities, particularly pulmonary (e.g. chronic
obstructive pulmonary disease) and cardiovascular dis-
ease. In addition 11% of our patients had a past history of
a previous malignancy, excluding non-melanoma skin
lesions and cervical cancer in situ. A total of 35 (19%)
patients were excluded for having non-measurable dis-
ease, previous malignancy and/or prior receipt of chemo-
therapy. Of these, 24 (69%) remained ineligible on other
grounds, and 11 patients were rendered ineligible on
these criteria only, and would not necessarily have been
restricted from receiving chemotherapy off trial.
The major limitation of this study is that it is not popula-
tion based. Due to failure of physicians to complete the
questionnaire on every new patient presenting to the Syd-
ney Cancer Centre with advanced NSCLC, we were not
able to prospectively survey consecutive patients. Exami-
nation of our lung cancer data base reveals that it is likely
that our study obtained data on 93% of patients who had
presented to the Sydney Cancer Centre with advanced
NSCLC during the study period; although almost half of
the data were obtained retrospectively. However, our
study likely underestimates the number of patients that
would be excluded from advanced NSCLC trials, as the
sickest patients and patients with other co-morbidities are
often not referred to a Cancer Centre, but instead are man-
aged by their family physician, geriatrician or palliative
care services with symptomatic treatment only. It is likely
that a true population based study would result in an even
smaller percent of patients meeting inclusion criteria.
Whilst cisplatin-based chemotherapy regimens have been
shown to increase survival and quality of life in patients
who are eligible for large clinical trials compared to those
treated with best supportive care, we need to recognise
limitations in generalisability of results of those trials to
the broader population with advanced lung cancer. The
median age of our cohort was 68 years, consistent with the
median age of presentation of patients with advanced
NSCLC, whereas the median age in E1594, SWOG9509
and TAX326 was 61–63 years. It is only recently that we
have seen the emergence of studies investigating the
effects of chemotherapy in the elderly[11,12], as well as
ongoing studies in those with poorer performance status.
Conclusion
Our study demonstrates that 65–71% of ANSCLC patients
presenting to Sydney Cancer Centre, would not have been
Table 4: Number (%) of Ineligible Patients Based on Trials Exclusion Criteria*
E1594 SWOG 9509
Prospective Data
N = 100 (%)
Retro-spective Data
N = 85 (%)
Entire Cohort
N = 185 (%)
Prospective Data
N = 100 (%)
Retro-spective Data
N = 85 (%)
Entire Cohort
N = 185 (%)
Performance Status 37 (37%) 35 (41%) 72 (39%) 37 (37%) 35 (41%) 72 (39%)
Co-morbidities 19 (19%) 31 (36%) 50 (27%) 34 (34%) 41 (48%) 75 (40%)
Previous History of Cancer 12 (12%) 9 (11%) 21 (11%) 12 (12%) 9 (10.5%) 21 (11%)
Brain Metastases 14 (14%) 1 (1%) 15 (8%) 14 (14%) 1 (1%) 15 (8%)
Non Evaluable or Non 
Measurable Disease
9 (9%) 1 (1%) 10 (5%) 9 (9%) 1 (1%) 10 (5%)
Abnormal Blood Parameter 2 (2%) 6 (7%) 8 (4%) 2 (2%) 7 (8%) 9 (5%)
Previous Chemotherapy 2 (2%) 10 (12%) 12 (6.5%) 2 (2%) 10 (12%) 12 (6.5%)
Unable to give Informed 
Consent
1 (1%) 3 (3.5%) 4 (2%) 1 (1%) 3 (3.5%) 4 (2%)
* Does not equal 100% due to many patients being excluded on more than one criterion – see Table 3Publish with BioMed Central    and   every 
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eligible for the major lung cancer trials E1594, SWOG
9509 and TAX356. There is a lack of evidence-based data
on which to base treatment decisions in the majority of
patients with advanced NSCLC. The optimal treatment for
these patients is not known.
Our recommendations are that future trials need to be
developed with more liberal eligibility and/or to target
specific subsets of patients within the population with
advanced NSCLC to ensure that results are applicable to
more patients.
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